A Variant of the Il2ra/Cd25 Gene Predisposing to Graves' Disease is Associated with Increased Levels of Soluble Interleukin-2 Receptor

Scandinavian Journal of Immunology

Volumn 74, Issue 5, 2011, Pages 496-501

  Chistiakov, D A ^a   Chistiakova, E I ^b   Voronova, N V ^b   Turakulov, R I ^c   Savost'anov, K V ^a  

^a STATE RESEARCH INSTITUTE OF GENETICS AND SELECTION OF INDUSTRIAL MICROORGANISMS   (Russian Federation)

^b N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR ALPHA; SOLUBLE INTERLEUKIN 2 RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENOTYPE; GRAVES DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GRAVES DISEASE; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; POLYMORPHISM, GENETIC; RUSSIA;

EID: 80053494417     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2011.02608.x     Document Type: Article

References (48)

1. Kurreeman FA, Daha NA, Chang M et al. Association of IL2RA and IL2RB with rheumatoid arthritis: a replication study in a Dutch population. Ann Rheum Dis 2009;68:1789-90.
2. Stahl EA, Raychaudhuri S, Remmers EF et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010;42:508-14.
3. Hinks A, Ke X, Barton A et al. Association of the IL2RA/CD25 gene with juvenile idiopathic arthritis. Arthritis Rheum 2009;60:251-7.
4. Matesanz F, Caro-Maldonado A, Fedetz M et al. IL2RA/CD25 polymorphisms contribute to multiple sclerosis susceptibility. J Neurol 2007;254:682-4.
5. Weber F, Fontaine B, Cournu-Rebeix I et al. IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun 2008;9:259-63.
6. Vella A, Cooper JD, Lowe CE et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am J Hum Genet 2005;76:773-9.
7. Lowe CE, Cooper JD, Brusko T et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 2007;39:1074-82.
8. Alcina A, Fedetz M, Ndagire D et al. IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D). PLoS ONE 2009;4:e4137.
9. Brand OJ, Heward JM, Franklyn JA et al. Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin Endocrinol 2007;66:508-12.
10. Chistiakov DA, Voronova NV, Chistiakov PA. The crucial role of IL-2/IL-2RA-mediated immune regulation in the pathogenesis of type 1 diabetes, an evidence coming from genetic and animal model studies. Immunol Lett 2008;118:1-5.
11. Burchill MA, Yang J, Vang KB, Farrar MA. Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett 2007;114:1-8.
12. Willerford DM, Chen J et al. Interleukin-2 receptor a chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995;3:521-30.
13. Refaeli Y, van Parijs L, London CA, Tschopp J, Abbas AK. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 1998;8:615-23.
14. Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol 2003;74:961-5.
15. Saitoh O, Nagayama Y. Regulation of Graves' hyperthyroidism with naturally occurring CD4+CD25+ regulatory T cells in a mouse model. Endocrinology 2006;147:2417-22.
16. Nagayama Y, Horie I, Saitoh O, Nakahara M, Abiru N. CD4+CD25+naturally occurring regulatory T cells and not lymphopenia play a role in the pathogenesis of iodide-induced autoimmune thyroiditis in NOD-H2h4 mice. J Autoimmun 2007;29:195-202.
17. Saitoh O, Abiru N, Nakahara M, Nagayama Y. CD8+CD122+T cells, a newly identified regulatory T subset, negatively regulate Graves' hyperthyroidism in a murine model. Endocrinology 2007;148:6040-6.
18. Zwirska-Korczala K, Berdowska A, Jochem J et al. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders. J Clin Pharm Ther 2004;29:151-6.
19. Jiskra J, Antošová M, Límanová Z, Telička Z, Lacinová Z. The relationship between thyroid function, serum monokine induced by interferon gamma and soluble interleukin-2 receptor in thyroid autoimmune diseases. Exp Clin Immunol 2009;156:211-6.
20. Costagliola S, Swillens S, Noccoli P et al. Binding assay for thyrotropin receptor autoantibodies using the recombinant receptor protein. J Clin Endocrinol Metab 1992;75:1540-4.
21. Michelangeli VP, Poon C, Topliss DJ, Colman PG. Specific effects of radioiodine treatment on TSAb and TBAb levels in patients with Graves' disease. Thyroid 1995;5:171-6.
22. Feldt-Rasmussen U, Hoier-Madsen M, Bech K et al. Anti-thyroid peroxidase antibodies in thyroid disorders and non-thyroid autoimmune diseases. Autoimmunity 1991;9:245-54.
23. Ranade K, Chang MS, Ting CT et al. High-throughput genotyping with single nucleotide polymorphisms. Genome Res 2001;11:1262-8.
24. Bland JM, Altman DG. Statistics notes. The odds ratio. Br Med J 2000;320:1468.
25. Schneider S, Roessli D, Excoffier L. Arlequin ver. 2.000: A Software for Population Genetic Data Analysis. Switzerland: Genetics and Biometry Laboratory, University of Geneva, 2000.
26. Qu HQ, Montpetit A, Ge B, Hudson TJ, Polychronakos C. Toward further mapping of the association between the IL2RA locus and type 1 diabetes. Diabetes 2007;56:1174-6.
27. Maier LM, Lowe CE, Cooper J et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet 2009;5:e1000322.
28. Carr EJ, Clatworthy MR, Lowe CE et al. Contrasting genetic association of IL2RA with SLE and ANCA-associated vasculitis. BMC Med Genet 2009;10:22.
29. Qu HQ, Bradfield JP, Bélisle A et al. The type I diabetes association of the IL2RA locus. Genes Immun 2009;10:S42-8.
30. Cavanillas ML, Alcina A, Núñez C, de las Heras V et al. Polymorphisms in the IL2, IL2RA and IL2RB genes in multiple sclerosis risk. Eur J Hum Genet 2010;18:794-9.
31. Verlaan DJ, Ge B, Grundberg E et al. Targeted screening of cis regulatory variation in human haplotypes. Genome Res 2009;19:118-27.
32. Greenberg SJ, Marcon L, Hurwitz BJ, Waldmann TA, Nelson DL. Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. N Engl J Med 1989;319:1019-20.
33. Adachi K, Kumamoto T, Araki S. Interleukin-2 receptor levels indicating relapse in multiple sclerosis. Lancet 1989;1:559-60.
34. Gallo P, Piccinno MG, Pagni S et al. Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and gamma-IFN levels in serum and cerebrospinal fluid. J Neurol Sci 1989;92:9-15.
35. Maier LM, Anderson DE, Severson CA et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol 2009;182:1541-7.
36. Srivastava MD, Rossi TM, Lebenthal E. Serum soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in Crohn's disease, celiac disease, and systemic lupus erythematosus. Res Commun Mol Pathol Pharmacol 1995;87:21-6.
37. Cheng SP, Liu JL, Yuan J. Study of the effect of leeching on plasma endothelin and soluble interleukin-2 receptor in patients with systemic lupus erythematosus. Chin J Integr Med 2005;11:65-8.
38. Sfikakis PP, Charalambopoulos D, Vaiopoulos G, Mavrikakis M. Circulating P- and L-selectin and T-lymphocyte activation and patients with autoimmune rheumatic diseases. Clin Rheumatol 1999;18:28-32.
39. Kuuliala A, Söderlin M, Kautiainen H, Repo H, Leirisalo-Repo M. Circulating soluble interleukin-2 receptor level predicts remission in very early reactive arthritis. Scand J Rheumatol 2005;34:372-5.
40. Dedijca D. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy. Roum Arch Microbiol Immunol 2001;60:183-201.
41. Murakami S. Soluble interleukin-2 receptor in cancer. Front Biosci 2004;9:3085-90.
42. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199:971-9.
43. Pan D, Shin YH, Gopalakrishnan G, Hennessey J, De Groot LJ. Regulatory T cells in Graves' disease. Clin Endocrinol (Oxf) 2009;71:587-93.
44. Mao C, Wang S, Xiao Y et al. Impairment of regulatory capacity of CD4+CD25+regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves' disease. J Immunol 2011;186:4734-43.
45. Wang H, Zhao S, Tang X, Li J, Zou P. Changes of regulatory T cells in Graves' disease. J Huazhong Univ Sci Technolog Med Sci 2006;26:545-7.
46. Villarino AV, Tato CM, Stumhofer JS et al. Helper T cell IL-2 production is limited by negative feedback and STAT-dependent cytokine signals. J Exp Med 2007;204:65-71.
47. Eisenstein Z, Engelsman E, Weiss M, Kalechman Y, Sredni B. Modulation of the IL-2 production defect in vitro in Graves' disease. Clin Exp Immunol 1994;96:323-8.
48. Ward LS, Fernandes GA. Serum cytokine levels in autoimmune and non-autoimmune hyperthyroid states. Braz J Med Biol Res 2000;33:65-9.